RT Journal Article
SR Electronic
T1 Suicide risk with selective serotonin reuptake inhibitors and new-generation serotonergic-noradrenergic antidepressants in adults: a systematic review and meta-analysis of observational studies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.11.20098178
DO 10.1101/2020.05.11.20098178
A1 Michael P Hengartner
A1 Simone Amendola
A1 Jakob A Kaminski
A1 Simone Kindler
A1 Tom Bschor
A1 Martin Plöderl
YR 2020
UL http://medrxiv.org/content/early/2020/05/19/2020.05.11.20098178.abstract
AB Background There is ongoing controversy whether antidepressant use alters the suicide risk in adult routine-care patients with depression and other treatment indications. The aim of this study was thus to examine the suicide risk with antidepressants in observational studies, considering financial conflicts of interest (fCOI) and publication bias.Design Systematic review and meta-analysis.Main outcome measures Risk of suicide, suicide attempt and/or intentional self-harm.Data sources We searched MEDLINE, PsycINFO, Web of Science, PsycARTICLES and SCOPUS for case-control and cohort studies published 1990-2020.Eligibility criteria for study selection Cohort and case-control studies in adults (aged ≥18 years) with depression and any unspecified condition reporting suicide risk for patients exposed to selective serotonin reuptake inhibitors (SSRI) or new-generation serotonergic-noradrenergic antidepressants (SNA) relative to unexposed patients.Data extraction and analysis Effects were aggregated with a random-effects model and reported as relative risk estimates (RE) with 95%-confidence-intervals. We assessed heterogeneity via I2-statistics and publication bias via funnel-plot asymmetry and trim-and-fill method. Study fCOI was defined present when lead-authors’ professorship was industry-sponsored, they received payments from the industry, or when the study was industry-sponsored.Results We included 27 original studies in the meta-analysis; 19 on depression (including other affective and anxiety disorders) and 8 on any unspecified condition. Use of SSRI or SNA for depression was associated with increased suicide risk (comprising both suicide and suicide attempt), RE=1.29, 1.06-1.57. Risk estimates were significantly lower in studies with fCOI (Q=21.87, p<0.001) and the trim-and-fill method estimated that 12 studies were missing due to publication bias; the result with missing studies imputed was RE=1.61, 1.31-1.99. Use of SSRI or SNA for all conditions (including depression and any unspecified condition) was associated with increased suicide risk, RE=1.43, 1.21-1.68. Studies with fCOI reported significantly lower risk estimates (Q=34.19, p<0.001) and the trim-fill method estimated that 13 studies were missing; after imputation of missing studies the result was RE=1.72, 1.44-2.05. Quality of evidence was rated very low due to substantial inconsistency of between-study results (I2≥85%).Conclusions Exposure to new-generation antidepressants is associated with increased suicide risk in adult routine-care patients with depression and other conditions. Publication bias and fCOI contribute to systematic underestimation of risk estimates in the published literature.Registration Open Science Framework, https://osf.io/eaqwn/What is already known on this topic Meta-analyses of randomised controlled trials (RCT) found either no reduction of suicidal events or increased risk with new-generation antidepressants relative to placebo. However, generalisability of RCT findings is limited due to narrowly preselected participants, short study duration and treatment settings that are not representative of primary care routine practice. A previous meta-analysis of observational studies reported significantly reduced suicide risk in adults with depression exposed to selective serotonin reuptake inhibitors (SSRI), but it did not include new-generation serotonergic-noradrenergic antidepressants (SNA) and did not consider publication bias and study lead-authors’ financial conflicts of interest (fCOI).What this study adds Our results indicate that SSRI and SNA are associated with increased suicide risk in adult routine-care patients with depression and other psychiatric and non-psychiatric treatment indications. We further found empirical evidence for publication bias. Several studies with evidence of increased suicide risk with new-generation antidepressants likely remain unpublished. Accordingly, we found that study lead-authors with fCOI report significantly lower risk estimates than lead-authors without fCOI.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://osf.io/eaqwn/ Funding StatementNo funding was received for this particular studyAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and statistical code will be made freely available upon publication of the study in a scientific journal https://osf.io/eaqwn/